CNXU Stock Forecast: Conexeu Sciences, Inc. Price Predictions for 2026-2027

Last close, 20 Nov 2026
$1.54
−25.96% on the day

Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 1 of 100 as at 21 Nov 2026 — in the weakest quartile.

Market cap
$64.1M
Ticker Nerd rank
1/ 100
Median analyst target
$20
Analysts covering
—
Free cash flow−$1.8M
Quarterly, 4 quarters to 30 Apr 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−29.4%
1M
−48.5%
From high
−90.9%
From low
0.0%
$2
$17
Range since 21 May 2026, adjusted closes · the dot is the last close
Ticker Nerd rank

One number for the whole business

Consensus tells you what everyone already believes. The model scores Conexeu Sciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 21 Nov 2026
1/ 100

Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
20
Issuance
12
Growth
10
Value
7
Accruals
5
Quality
4
Volatility
1
Momentum
0

Revisions (20): Analysts have, on balance, been raising their forecasts.

Momentum (0): The shares have been drifting down relative to others.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

CNXU stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on CNXU, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, since 21 May 2026Adjusted close, US dollars
$0$5$10$15$20Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CNXUHigh $20Median $20Low $20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Recent analyst actionsNewest first
DateFirmActionRatingTarget
22 June 2026HC Wainwright & Co.InitiatesBuy$20

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

CNXU appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.

Free. Unsubscribe any time. Privacy

The AI build-out map
PDF
  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and servers

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

CNXU vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

CNXU vs S&P 500, last 12 monthsTotal return, rebased to 100
020406080100120Jun 26Jul 26Aug 26Sep 26Oct 26Nov 26CNXUS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

CNXU analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Financials

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
—
Price / sales
—
Price / book
7.2×

Cheaper than 11% of US stocks

EV / EBITDA
—
Growth & margins
Revenue growth (YoY)
—
Earnings growth (YoY)
—
Gross margin
—
Operating margin
—
Net margin
—
Returns & dividend
Return on equity
−332.9%

Higher than 4% of US stocks

Return on assets
−170.7%

Higher than 1% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.

Statistics

Key statistics

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Conexeu Sciences, Inc. has a market value of $64.1M and an enterprise value of $57.2M.

  • Shares outstanding: 20.9M.

Statement figures: company filings via Twelve Data, four quarters to 30 Apr 2026 · market figures as at 20 Nov 2026

Data provided by Twelve Data

Peers

CNXU and its peers

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
CNXUConexeu Sciences, Inc.$64.1M1
ONCYOncolytics Biotech, Inc.$47.7M38
HRTXHeron Therapeutics, Inc.$47.9M54
VRCAVerrica Pharmaceuticals, Inc.$47.1M49
IMAImageneBio, Inc.$48.8M33
ACRVAcrivon Therapeutics, Inc.$49.2M65
TNXPTonix Pharmaceuticals Holding Corp.$46.2M22

Take a look at CNXU’s peer groups, ranked by the model: healthcare stocks · biotech stocks.

Look up any of the roughly 4,300 stocks we score.

The rank is the raw material. Whether the rules would actually own Conexeu Sciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

FAQ

Questions about CNXU

How does Ticker Nerd's model rank CNXU?

As at 21 Nov 2026, Conexeu Sciences, Inc. ranks 1 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Revisions (20 of 100).

What is the CNXU stock forecast for 2030?

No analyst covering Conexeu Sciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CNXU are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $20 to $20 over the next 12 months.

What does Conexeu Sciences, Inc. do?

Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative biomaterial products for tissue restoration and repair. Its core platform centers on a temperature-responsive extracellular matrix scaffold designed to support soft-tissue regeneration in applications such as wound care, dental repair, and medical aesthetics.

Company

About Conexeu Sciences, Inc.

Conexeu Sciences Inc. is a biotechnology company focused on developing collagen-based regenerative biomaterial products for tissue restoration and repair. Its core platform centers on a temperature-responsive extracellular matrix scaffold designed to support soft-tissue regeneration in applications such as wound care, dental repair, and medical aesthetics. The company’s products are intended to provide physicians with device-based tools for restoring tissue structure and function across clinical settings, including facial rejuvenation and body contouring uses. Conexeu Sciences operates in the regenerative medicine space, where collagen scaffold technologies are used to support healing, tissue in-growth, and improved patient outcomes. The company is based in Reno, Nevada, and is positioned as an early-stage developer of novel biomaterial solutions for both therapeutic and aesthetic markets.

CEO Mr. Miles D. Harrison · United States · https://www.conexeu.com